Usted buscó: reaktiivsus (Estonio - Inglés)

oluline reaktiivsus (potentsiaal);
significant reactivity (potential);

füüsikalis-keemilised omadused ja keemiline reaktiivsus (3. etapp).
physicochemical properties and chemical reactivity (step 3).

füüsikaline laad ja füüsikalis-keemilised omadused (nt ph, lenduvus, lahustuvus, stabiilsus, reaktiivsus veega);
physical nature and physicochemical properties (e.g. ph, volatility, solubility, stability, reactivity with water),

pe teostatud, kuna puuduvad sobivad antikehamudelid, millel oleks vähene ristuv reaktiivsus närilise tnf- iga ja kuna närilistel tekivad neutraliseerivad antikehad.
tho fertility and postnatal toxicity, were not performed with adalimumab due to the lack of appropriate models for an antibody with limited cross-reactivity to rodent tnf and the development of neutralizing antibodies in rodents.

adalimumabiga ei ole kartsinogeensusuuringuid ega viljakuse ja postnataalse toksilisuse hindamist teostatud, kuna puuduvad sobivad antikehamudelid, millel oleks vähene ristuv reaktiivsus närilise tnf-iga ja närilistel tekkivatele neutraliseerivatele antikehadele.
neither carcinogenicity studies, nor a standard assessment of fertility and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an antibody with limited cross-reactivity to rodent tnf and to the development of neutralizing antibodies in rodents.

kartsinogeensuse uuringuid ustekinumabil läbi ei viidud, kuna puuduvad sobivad mudelid antikeha jaoks, millel on ristuv reaktiivsus näriliste il-12/23 p40-ga.
carcinogenicity studies were not performed with ustekinumab due to the lack of appropriate models for an antibody with no cross-reactivity to rodent il-12/23 p40.

adalimumabiga ei ole kartsinogeensusuuringuid ega reproduktsiooni- ja postnataalse toksilisuse hindamist teostatud, kuna puuduvad sobivad antikehamudelid, millel oleks vähene ristuv reaktiivsus närilise tnf-iga ja närilistel tekkivatele neutraliseerivatele antikehadele.
neither carcinogenicity studies, nor a standard assessment of fertility and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an antibody with limited cross-reactivity to rodent tnf and to the development of neutralizing antibodies in rodents.

enne ravi alustamist peab ravi määrav arst olema veendunud, et täiskasvanud ja noorukieas patsiendil ige tasemega alla 76 rÜ/ml ja lastel (6…<12-aastased) ige tasemega alla 200 rÜ/ml on püsiv in vitro reaktiivsus (rast) aastaringsele allergeenile.
prescribing physicians should ensure that adult and adolescent patients with ige below 76 iu/ml and children (6 to < 12 years of age) with ige below 200 iu/ml have unequivocal in vitro reactivity (rast) to a perennial allergen before starting therapy.